For much of biotechnology's history, investors tended to focus on one question above all others: does the science work?

Encouraging clinical data could transform an early-stage company almost overnight, while disappointing trial results often erased years of progress. Scientific innovation remains the foundation of every successful biotechnology company, but the industry's definition of competitive advantage is beginning to evolve.

Today, promising science alone is rarely enough.

As oncology drug development becomes increasingly complex, companies are being evaluated on their ability to execute across every stage of development—from translational research and biomarker discovery to regulatory strategy, manufacturing readiness, and commercialization planning. Success is no longer determined by a single clinical milestone. It's increasingly measured by whether an organization can consistently translate scientific promise into a disciplined development program.

That shift reflects the changing realities of modern oncology.

Cancer therapies are becoming more personalized, combination strategies are replacing one-size-fits-all approaches, and regulators are engaging with developers earlier than ever before to help guide programs addressing serious diseases with significant unmet medical need. Each of those trends places greater emphasis on operational execution alongside scientific discovery.

The evolution is evident across much of the biotechnology sector, including at Oncolytics Biotech (NASDAQ: ONCY).

The company's investigational immunotherapy, pelareorep, has attracted attention through clinical studies evaluating its role as an immune primer alongside established cancer therapies. Rather than positioning pelareorep as a replacement for existing standards of care, Oncolytics has concentrated on understanding where combination strategies may improve patient outcomes by activating both the innate and adaptive immune systems and making tumors more responsive to immunotherapy.

That scientific strategy has been matched by an equally deliberate development strategy.

The company's recent FDA Fast Track designation for pelareorep in combination with a checkpoint inhibitor in second-line and later squamous cell carcinoma of the anal canal illustrates how regulatory engagement has become an integral part of modern drug development. Fast Track does not predict approval, but it provides more frequent interaction with the FDA and helps align clinical development with regulatory expectations as evidence continues to evolve.

At the same time, Oncolytics has expanded randomized clinical development in RAS-mutant, microsatellite-stable metastatic colorectal cancer, a disease where immunotherapy has historically shown limited benefit. Rather than relying solely on clinical endpoints, the company is pairing efficacy evaluation with biomarker-driven translational research designed to better understand why certain patients respond and how future studies can become increasingly precise.

That integration of science and execution is becoming increasingly important throughout biotechnology.

Intellectual property is no longer limited to protecting discoveries. Manufacturing know-how, scalable production processes, regulatory planning, and organizational readiness have become strategic assets in their own right. Likewise, partnerships are evolving beyond simple licensing arrangements into collaborations that expand scientific understanding, accelerate clinical development, and prepare companies for eventual commercialization.

The result is a different way of thinking about biotechnology companies.

Scientific innovation remains the catalyst that begins every development program. But investors, regulators, clinicians, and potential commercial partners increasingly look for evidence that management teams can execute consistently across the entire development lifecycle. That includes designing scientifically rigorous trials, integrating translational research, engaging regulators constructively, protecting manufacturing capabilities, and building organizations capable of supporting future commercialization.

Whether pelareorep ultimately reaches patients will depend on the results of ongoing and future clinical studies. Yet the broader lesson extends well beyond any single investigational therapy. Biotechnology is entering a period where the companies best positioned for long-term success may not simply be those with the most promising science—they may be the ones that combine scientific innovation with operational discipline at every stage of development.